晚期高级别浆液性卵巢癌合并输卵管上皮内癌的临床意义
本研究基于纪念斯隆凯特琳癌症中心的前瞻性数据库,纳入2015年1月至2018年12月接受初次肿瘤细胞减灭术的306例高级别浆液性卵巢癌患者,其中87例(28%)合并输卵管上皮内癌(STIC)。结果显示,合并与不合并STIC的患者在无进展生存期和总生存率上无显著差异,且驱动突变和结构遗传学改变分布相似。结论提示,合并STIC并未带来可识别的临床或遗传学差异。
要点
- 28%的高级别浆液性卵巢癌患者合并STIC,两组人口学和临床病理因素相似。
- 不合并STIC组术前CA-125中位数显著更高(423 U/mL vs. 321 U/mL,p=0.029)。
- 两组无进展生存期和3年总生存率无显著差异,驱动突变分布相似。
核心结论
- 合并STIC的高级别浆液性卵巢癌患者与不合并者在临床和遗传学上无显著差异,提示可能为同一疾病过程。
研究设计与样本
- 回顾性队列研究,基于纪念斯隆凯特琳癌症中心前瞻性维护的机构数据库,纳入2015年1月至2018年12月接受初次肿瘤细胞减灭术的306例高级别浆液性卵巢癌患者。
- 根据最终病理是否合并STIC分为两组:+STIC组87例(28%),no-STIC组219例(72%)。
- 比较人口学、围手术期和结局数据,采用Kaplan-Meier法评估生存,使用MSK-IMPACT进行靶向DNA测序比较体细胞变异。
主要发现
- 两组人口学和临床病理因素相似,仅no-STIC组术前CA-125中位数显著更高(423 U/mL vs. 321 U/mL;p=0.029)。
- +STIC组与no-STIC组的中位无进展生存期分别为22.7个月(95%CI: 18.9-28.4)和27.7个月(95%CI: 25.5-30.5),差异无统计学意义(p=0.126)。
- +STIC组与no-STIC组的3年总生存率分别为81%(95%CI: 70-88%)和85%(95%CI: 78-90%),差异无统计学意义(p=0.392)。
- MSK-IMPACT测序显示两组驱动突变或结构遗传学改变分布相似,受累遗传信号通路相似。
临床怎么用
- 对于高级别浆液性卵巢癌患者,合并STIC的存在与否不影响生存预后评估。
- 术前CA-125水平较低可能提示合并STIC,但需结合病理确认。
- STIC状态不应作为改变治疗策略的依据,仍需按标准方案管理。
局限性
- 本研究为单中心回顾性分析,样本量有限。
- STIC诊断基于最终病理,可能存在 sampling 偏倚。
- 未报告具体的突变频率和通路细节,基因组分析为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical significance and genomic associations of concurrent serous tubal intraepithelial carcinoma (STIC) with high-grade serous carcinoma (HGSC) of the ovary in women undergoing primary debulking surgery (PDS). METHODS: All patients who underwent PDS for HGSC between 01/2015 and 12/2018 were captured in a prospectively maintained institutional database. Patients were categorized based on the presence or absence of concurrent STIC noted on final pathology. Demographic, perioperative, and outcomes data were collected, and groups were compared using standard statistical tests. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method. For comparison of differences in somatic alterations between the two cohorts, specimens were sequenced using MSK-IMPACT. RESULTS: Of 306 eligible patients, 87 (28%) had a concurrent STIC lesion (+STIC) and 219 (72%) did not (no-STIC). Demographics and clinicopathological factors were similar between the two cohorts, except for a significantly higher median preoperative CA-125 level in the no-STIC group (423 U/mL vs. 321 U/mL; p=0.029). There were no significant differences in median PFS (22.7 months [95%CI: 18.9-28.4] vs. 27.7 months [95%CI: 25.5-30.5]; p=0.126) and 3- year OS rate (81% [95%CI: 70-88%] vs. 85% [95%CI: 78-90%]; p=0.392) between +STIC and no-STIC patients, respectively. Targeted DNA-sequencing via MSK-IMPACT showed a similar distribution of driver mutations or structural genetic alterations, and affected genetic signaling pathways were similar between the cohorts. CONCLUSIONS: There were no identifiable clinical and genetic differences in patients with HGSC and concurrent STIC. These data suggest a comparable, if not identical, disease process.
引用
- Boerner T, Walch HS, Nguyen B, et al. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecol Oncol. 2020. PMID: 33386131. doi:10.1016/j.ygyno.2020.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。